Abstract
Background and Aims Oesophagogastro duodenoscopies (OGD) are aerosol generating procedures (AGP) that may spread respiratory pathogens. We aim to investigate production of airborne aerosols and droplets during Cytosponge procedures, which are being evaluated in large-scale research studies and NHS implementation pilots to reduce endoscopy backlogs.
Design and Methods We measured 18 Cytosponge and 37 OGD procedures using a particle counter (diameters 0.3μm-25μm) taking measurements 10cm from the mouth. Two particle count analyses were performed: whole procedure and event-based.
Results Direct comparison with duration-standardised OGD procedures shows Cytosponge procedures produce 2.16x reduction (p<0.001) for aerosols and no significant change for droplets (p=0.332). Event-based analysis shows particle production is driven by throat spray (aerosols:138.1x reference, droplets:16.2x), which is optional, and removal of Cytosponge (aerosols:14.6x, droplets:62.6x). Cytosponge coughing produces less aerosols than OGD (2.82x, p<0.05).
Conclusions Cytosponge procedures produce significantly less aerosols and droplets than OGD procedures and thus reduce two potential transmission routes for respiratory viruses.
Competing Interest Statement
Rebecca Fitzgerald is named on patents related to Cytosponge and assays which have been licensed by the Medical Research Council to Covidien (now Medtronic). RCF is a co-founder and shareholder (<3%) for Cyted Ltd.
Funding Statement
The authors thank Norgine Pharmaceuticals for sponsoring the purchase of a particle counter. GSDG acknowledges a UKRI Future Leaders Fellowship (MR/T041951/1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval was obtained from Wales Ethics Committee Integrated Research Application System (IRAS) no. 285595 and England Research Ethics Committee IRAS no. 283505, amendment 3.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
George.Gordon{at}nottingham.ac.uk
Samantha.Warburton{at}nuh.nhs.uk
Sian.Parkes{at}nuh.nhs.uk
amk88{at}cam.ac.uk
Adolfo.Parra-Blanco{at}nottingham.ac.uk
DATA AVAILABILITY STATEMENT Data associated with this publication is available at http://dx.doi.org/10.17639/nott.XXX Code used for data analysis in this publication can be found at https://github.com/gsdgordon/aerosols
FUNDING The authors also thank Norgine Pharmaceuticals for sponsoring the purchase of a particle counter. GSDG acknowledges a UKRI Future Leaders Fellowship (MR/T041951/1).
CONFLICTS OF INTERESTS RCF is named on patents related to Cytosponge and assays which have been licensed by the Medical Research Council to Covidien (now Medtronic). RCF is a co-founder and shareholder (<3%) for Cyted Ltd.
Data Availability
Data associated with this publication is available at http://dx.doi.org/10.17639/nott.XXX Code used for data analysis in this publication can be found at https://github.com/gsdgordon/aerosols
